pembrolizumab,gemcitabine
merck
['mibc', 'pembro', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', ' gem ', 'gemcitabine']
followed by #gu14188 mibc (t2-t4an0m0) study by #gu23: phase 1b/2 of adding pembro to gem/cis (cohort a, n=43) vs pembro to gem for cis-ineligible (cohort b, n=38) met primary endpoint of pathologic downstaging (pair) with 61% in cohort a &amp; 52% in cohort b 
GU Oncologist | 🇨🇦 GU & NOLA Heme/Onc Alumni | Interested in GU, Immuno Onc & Med Ed | @ASCO Featured Voice | @TwoOncDocs podcast